Cutaneous T-Cell Lymphoma (CTCL) Recruiting Phase 1 Trials for Alemtuzumab (DB00087)

Also known as: Lymphoma, Cutaneous T-Cell / Cutaneous T-Cell Lymphomas / Cutaneous T-Cell Lymphoma / Cutaneous lymphoma / Lymphoma, T-Cell, Cutaneous

IndicationStatusPhase
DBCOND0071861 (Cutaneous T-Cell Lymphoma (CTCL))Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02689453Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)Treatment